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Does Early Resumption of Low-Dose Aspirin After
Evacuation of Chronic Subdural Hematoma With
Burr-Hole Drainage Lead to Higher Recurrence
Rates?
BACKGROUND: Antiplatelet therapy in patients with chronic subdural hematoma
(cSDH) presents significant neurosurgical challenges. Given the lack of guidelines
regarding perioperative management with antiplatelet therapy, it is difficult to balance
the patient’s increased cardiovascular risk and prevalence of cSDH.
OBJECTIVE: To better understand the risk and recurrence rates related to resuming
low-dose acetylsalicylic acid (ASA) by evaluating our patients’ resumption of low-dose
ASA at various times after burr-hole drainage of the hematoma.
METHODS: In our retrospective study, 140 consecutive patients taking low-dose ASA
undergoing surgical evacuation of cSDH were included. Data included baseline char-
acteristics and rates of recurrence, morbidity, and mortality. A multivariate logistic
regression model analyzed the association between ASA resumption time and recur-
rence rates.
RESULTS: No statistically significant association was observed between early post-
operative resumption of low-dose ASA and recurrence of cSDH (odds ratio, 1.01; 95%
confidence interval, 1.001-1.022; P = .06). Corresponding odds ratios and risk differences
for restarting ASA treatment on postoperative days 1, 7, 14, 21, 28, 35, or 42 were
estimated at 1.53 and 5.9%, 1.42 and 5.1%, 1.33 and 4.1%, 1.23 and 3.2%, 1.15 and 2.2%,
1.07 and 1.1%, and 1.01 and 0.2%, respectively (P . .05). Cardiovascular event rates,
surgical morbidity, and mortality did not significantly differ between patients with or
without ASA therapy.
CONCLUSION: Given the few published studies regarding ASA use in cranial neuro-
surgery, our findings elucidate one issue, showing comparable recurrence rates with
early or late resumption of low-dose ASA after burr-hole evacuation of cSDH.
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A
cetylsalicylic acid (ASA) is a drug widely
prescribed for the primary and secondary
prevention of coronary artery disease
(CAD).1,2 ASA has been shown to reduce the
risk of cardiovascular death or subsequent attacks
in patients with previous myocardial infarction,
unstable angina, stroke, or transient ischemic
attacks.3,4 Nearly 40% of the patients who
undergo noncardiac surgery worldwide have or
are at risk of CAD; of these, 4%/y develop
a major intraoperative cardiovascular complica-
tion, including cardiac death, nonfatal myocar-
dial infarction, and cardiac arrest.5,6 In-hospital
mortality caused by perioperative myocardial
infarction ranges from 15% to 25%.6-8
The incidence of chronic subdural hematoma
(cSDH) is estimated at 1.7 to18per 100 000 people
and rises to 58 per 100 000 in people.65 years of
age.9 Its significantly higher prevalence among
patients . 65 years of age (69%) vs younger
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patients taking platelet aggregation inhibitors or oral anticoagu-
lants.10 Antiplatelet therapy in patients with cSDH presents
a significant neurosurgical challenge. Although patients seem to be
at greater risk for cSDH while taking these medications, it remains
unclear how antiplatelet therapy affects recurrence rates.9,11-13
Despite no definitive evidence for the preoperative discontinuation
of antiplatelet therapy, most surgeons prefer to discontinue or to
revert antiplatelet therapy before surgery.14 Once discontinued, the
optimal timing for the postoperative resumption of antiplatelet
therapy is not defined.15 Of course, ASA is typically resumed as soon
as possible in patients at risk for major perioperative cardiovascular
complication, even though its early postoperative resumption might
lead to higher cSDH recurrence rates.
In balancing the increased cardiovascular risk with increasing
prevalence of cSDH, a lack of guidelines and recommendations
persists regarding the perioperative management of patients with
antiplatelet therapy. In this study of patients who underwent burr-
hole evacuation of cSDH,we examine recurrence rates, morbidity,
and mortality related to the timing of resuming low-dose ASA
therapy.
METHODS
In this retrospective review of 750 consecutive patients who underwent
evacuation of cSDH by burr-hole drainage (January 2009-June 2014),
there were 391 patients from the University Hospital of Basel and 359
patients from the Kantonsspital of Aarau. Of these, 144 patients (19.2%),
including 38 women (26.3%) and 106 men (73.7%), were taking low-
dose ASA (aspirin cardio 100 mg once daily) before surgery; 4 patients
(2.77%) were then excluded because of missing information on ASA use.
Medical records and radiological findings were reviewed for 140 patients,
including clinical variables such as age, sex, side of the cSDH,
comorbidities, presenting symptoms, and concomitant antiplatelet
therapy (Tables 1 and 2). The study protocol was approved by the
local ethics committee (EKNZ, Basel, Switzerland). For this retrospec-
tive study, patient consent was not sought because the administrative
burden would be disproportionately large and therefore consent is not
necessary according to local ethics guidelines.
The diagnosis of all patients was symptomatic, 1-sided, or bilateral
cSDH confirmed by computed tomography or magnetic resonance
imaging. All patients were treated surgically with burr-hole drainage,
irrigation of the hematoma, and insertion of a drain without suction for 48
hours postoperatively. Indication for surgery was a hematoma .1 cm
leading to neurological symptoms. Patients who presented with an acute
subdural hematoma and those who underwent a craniotomy were
excluded from the study.
In 32 patients (22.9%) presenting with minor symptoms (headache,
gait disturbance, etc), ASA was discontinued at least 5 days before elective
surgery. The other 108 patients (77.1%) underwent emergency burr-hole
evacuation under the effect of ASA treatment; 80 patients (74.1%) had
taken ASA the day of surgery, whereas 12 (11.1%), 8 (7.4%), 3 (2.8%),
and 5 (4.6%) patients had discontinued ASA treatment 1, 2, 3, and 4 days
before the operation, respectively. The decision on when to resume ASA
treatment postoperatively was based on the surgeons’ personal experience
and considerations about its initial indications for use. In 32 patients
(22.9%), the indication for ASA treatment was not confirmed post-
operatively, and the treatment was stopped.
The primary end point of the study was recurrence that required
revision surgery owing to clinical symptoms. The secondary end points
were major cardiovascular events (eg, ST-segment–elevation myocardial
infarction, defined as ST-segment elevation on electrocardiogram of .1
mm in at least 1 derivation with or without clinical symptoms of
myocardial infarction, and non-ST-segment elevation myocardial










M/F 102/38 85/36 17/2 .10
Location, left/right/bilateral 60/50/30 49/46/26 11/4/4 .31
ASA discontinued
preoperatively, .5 d/,5 d




20 15 5 .15
CAD 76 63 13 .22
Coronary stent 26 20 6 .12
Arterial hypertension 102 88 14 ..99
Coronary bypass 7 7 0 .60
Diabetes mellitus 20 17 3 .74
Transient ischemic attack/
cerebrovascular insult
18 16 2 ..99
Peripheral artery occlusive
disease
8 7 1 .35
Carotid stent 2 1 1 .25
Atrial fibrillation 16 13 3 .46
Hypercholesterolemia 33 31 2 .24
aASA, acetylsalicylic acid; CAD, coronary artery disease; cSDH, chronic subdural
hematoma.





No (n = 121),
Mean 6 SD




Age, y 77.3 6 8.3 77.4 6 8.4 76.7 6 7.4 .73
Operation
time, min
59.8 6 26.9 60.3 6 27.8 55.5 6 20.3 .79
Hospitalization
time, d
9.8 6 5.6 9.4 6 5.2 12.8 6 7.1 .03b
Preoperative
GCS score
13.8 6 2.5 13.9 6 2.4 13.5 6 3.1 .74
Postoperative
GCS score
14.6 6 1.5 14.7 6 1.3 14.0 6 2.2 .07
Postoperative
mRS score
0.9 6 1.3 0.78 6 1.2 1.78 6 1.5 .03b
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infarction, defined as troponin elevation of at least 7 ng/L within 3-4
hours with or without clinical symptoms of myocardial infarction
without ST-segment elevation on electrocardiogram), cerebrovascular
insult, morbidity, and mortality.
All 140 patients were followed up clinically (mean, 43.5 days
postoperatively); of these, 112 patients (80%) had a postoperative
computed tomography scan (mean, 38.2 days).
Statistical Analysis
The association between ASA resumption (in days) and recurrence rate
was analyzed with a logistic regression model. Continuous variables were
the number of days from surgery to ASA resumption. The association was
assessed by change in odds ratio (OR) by days until ASA use resumed.
Confidence intervals (CIs) were calculated as previously described.16
Additionally, the corresponding OR and risk difference (RD) for
resuming ASA treatment were calculated for immediately after surgery
vs days 1, 7, 14, 21, 28, 35, and 42. Possible confounders assessed by
a supportive multivariate logistic regression analysis used the following
covariables: age, sex, preoperative and postoperative Glasgow Coma Scale
(GCS) scores, postoperative modified Rankin Scale (mRS) score (6-point
scale measuring the extent of disability and dependence in daily activities,
ranging from 0 = no symptoms to 6 = death), days ASA treatment was
discontinued before surgery, and concomitant blood thinners (eg,
clopidogrel, vitamin K antagonists). Calculations were then repeated,
excluding all 32 patients instructed not to resume ASA treatment
postoperatively because of their potential to fundamentally differ in
recurrence rates from those who resumed ASA.
Planning of methodology and statistical analyses was completed with
cooperation from a statistician (S.S.) of the Clinical Trial Unit of the
University Hospital of Basel. Statistical calculations were done with R
(Comprehensive R Archive Network, R Foundation for Statistical
Computing, Vienna, Austria). Categorical data were analyzed with the
Fisher exact test, and continuous data were analyzed with the Mann-
Whitney U test. A value of P , .05 was considered significant.
RESULTS
Effect of ASA Resumption on the Recurrence Rate
of cSDH
cSDH recurrences developed in 18 of the 108 patients (16.7%)
who resumed low-dose ASA postoperatively and in 1 of 32 patients
(3.1%) who never resumed ASA (P = .07). No significant
associations were seen between the time of resuming ASA
treatment postoperatively and recurrence rate of cSDH (OR,
1.01; 95% CI, 1.022-1.001; P = .06).
The distribution of recurrent events by recommencement of ASA
is shown in Table 3. Considering all 140 patients, the risk of
recurrence after resuming ASA treatment earlier was estimated at
1%/wk. The calculated OR and RD for recurrent cSDH when
ASA treatment was restarted on postoperative day 1, 7, 14, 21, 28,
35, or 42 were estimated at 1.53 and 5.9%, 1.42 and 5.1%, 1.33
and 4.1%, 1.23 and 3.2%, 1.15 and 2.2%, 1.07 and 1.1%, and
1.01 and 0.2%, respectively (P . .05; Table 4). In the subanalysis
that excluded the 32 patients who never resumed ASA use
postoperatively, no significant association between ASA resumption
time and recurrent events was found (OR, 1.004; 95% CI, 0.985-
1.022; P = .68); however, once ASA treatment was restarted earlier,
recurrence rates dropped to approximately 0.4%/wk. Among
patients who eventually resumed ASA treatment, the calculated
OR and RD of experiencing a recurrent cSDH when restarting
treatment on the postoperative day 1, 7, 14, 21, 28, 35, or 42 was
estimated at 1.18 and 2.4%, 1.15 and 2.0%, 1.12 and 1.6%, 1.08
and 1.2%, 1.06 and 0.82%, 1.03 and 0.4%, and 1.01 and 0.1%,
respectively (P . .05; Table 4).
Analysis of Potential Confounders
After adjustment for potential confounders, we again found no
association between ASA resumption time and increased recur-
rence rate of cSDH (Table 5). Low postoperative GCS score (OR,
1.28; 95% CI, 0.99-1.66; P = .04) and worse postoperative mRS
score (OR, 1.59; 95% CI, 1.14-2.23; P = .006) were found to be
independent risk factors significantly increasing the recurrence of
cSDH (Table 5). In multivariate analysis excluding patients who
never resumed ASA postoperatively, timing of ASA treatment
resumption was not associated with higher recurrence rates.
However, low postoperative GCS score (OR, 1.43; 95% CI,
1.02-2.13; P = .04) and worse postoperative mRS score (OR,
1.58; 95% CI, 1.10-2.31; P = .02) remained independent risk
factors that significantly increased the recurrence of cSDH.
Interestingly, the days of ASA discontinuation preoperatively had
no impact on recurrence rates. Therefore, we concluded that
evacuation of hemorrhage in a patient while taking ASA did not
significantly increase cSDH recurrence rates in our patients.
Major Cardiovascular Events
Postoperative cardiovascular events occurred in 10 patients
(7.1%), with no significant difference between 9 patients (6.9%)
who continued or 1 patient (11.1%) who discontinued ASA
treatment (P = .21; Table 6). Similarly, the individual rates of
myocardial infarction and other cardiovascular events (eg,
peripheral artery occlusion, pulmonary embolism) were not
significantly different between patients under continuous or
TABLE 3. Resumption of ASA Treatment and Recurrent Eventsa
ASA Treatment Patients, n
Recurrent
Events, n (%)
ASA not discontinued (,5 d) 9 2 (22.2)
ASA discontinued
5-7 d 20 2 (10.0)
8-14 d 17 4 (23.5)
15-28 d 12 2 (16.7)
29-42 d 24 6 (25.0)
43-90 d 26 2 (7.7)
ASA treatment resumed 108 18 (16.7)b
ASA treatment never resumed 32 1 (3.1)b
aASA, acetylsalicylic acid.
bP = .07.
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discontinued ASA treatment (Table 6). All cardiovascular events
occurred after postoperative day 7 (range, 8-34 days).
Surgical Morbidity
Surgical morbidity rates of 11.1% (n = 1) in patients with
continuous ASA treatment and 14.5% (n = 19) in patients with
discontinued ASA treatment were not statistically different (P .
.99). Surgical morbidities were meningitis in 1 patient, epileptic
seizures in 7 patients, wound infection in 5 patients (2 underwent
surgery, 3 were treated conservatively with antibiotics), intra-
parenchymal hemorrhage in 4 patients, and subdural empyema
requiring revision surgery in 4 patients.
Mortality
One patient (11.1%) who continued ASA use developed
postoperative meningitis and intraparenchymal hemorrhage
requiring recraniotomy and died of acute renal failure. Mortality
rate was 3.1% in the 4 patients who discontinued ASA; causes of
death were subdural empyema requiring revision surgery,
pulmonary embolism with exacerbated pulmonary infection,
postoperative intraparenchymal hemorrhage that required
decompressive hemicraniectomy, and sepsis with cardiopulmo-
nary decompensation. Mortality rates did not significantly differ
between patients who continued or discontinued ASA treatment
(P = .26; Table 6).
DISCUSSION
Given the sparse studies, mostly case reports, investigating the
effect of ASA therapy in cranial neurosurgery, the issue of whether
low-dose ASA should be discontinued after elective intracranial
surgery remains. Aiming to examine its effects in our 140 patients
who underwent evacuation for cSDH, we found no significant
association between timing of resuming low-dose ASA use post-
operatively and recurrent hemorrhage. Specifically, the RD for
recurrence was 1%/wk for resuming ASA in all patients and 0.4%/
wk when the 32 patients who never resumed ASA were excluded.
We identified a trend toward lower recurrence rates in patients
who never resumed low-dose ASA postoperatively (P = .07).
Therefore, if no definitive guideline-based primary or secondary
prevention indication exists, ASA therapy should not be resumed.
We found no significant association between discontinued ASA
TABLE 5. Multivariate Analysis of Confoundersa
Confounder OR (95% CI) P Value
Effect on the Main Analysisb
OR (CI) P Value
Age 1.01 (0.94-1.06) .8 1.01 (1.00-1.03) .06
Male sex 3.57 (0.93-25.0) .11 1.01 (1.00-1.03) .06
Concomitant blood thinner therapy 1.90 (0.54-6.12) .29 1.009 (1.00-1.02) .09
Discontinuation of ASA before surgery, d 1.05 (0.97-1.25) .40 1.009 (1.00-1.02) .06
Preoperative GCS score 1.06 (0.87-1.25) .49 1.01 (1.00-1.03) .06
Postoperative GCS score 1.28 (0.99-1.67) .04c 1.01 (1.00-1.03) .047c
mRS 1.59 (1.14-2.23) .006c 1.009 (1.00-1.02) .09
aASA, acetylsalicylic acid; CI, confidence interval; GCS, Glasgow Coma scale; mRS, modified Rankin Scale; OR, odds ratio.
bEffect of the cofounders on the OR of recurrence rate if ASA is resumed earlier.
cSignificant.
TABLE 4. Risk of Recurrence and Days of Postoperative ASA Resumptiona
Timing of Postoperative
ASA Resumption, d OR All (95% CI CI)b (n = 140) RD, % OR ASA (95% CI)b (n = 108) RD, %
1 1.53 (1.043-2.545) 5.93 1.18 (0.331-1.869) 2.38
7 1.42 (1.035-2.179) 5.06 1.15 (0.594-2.513) 2.01
14 1.33 (1.028-1.864) 4.14 1.12 (0.478-1.517) 1.62
21 1.23 (1.021-1.594) 3.17 1.08 (0.732-1.739) 1.23
28 1.15 (1.014-1.365) 2.16 1.06 (0.812-1.446) 0.82
35 1.07 (1.007-1.168) 1.11 1.03 (0.901-1.203) 0.42
42 1.01 (1.001-1.022) 0.16 1.01 (0.985-1.027) 0.06
aASA, acetylsalicylic acid; CI, confidence interval; OR All, odds ratio of recurrence when resuming ASA treatment in all patients; OR ASA, odds ratio of recurrence only in
patients in whom ASA treatment was eventually resumed; RD, risk difference.
bAll values are estimated calculations with a nonsignificant P value of .06.
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use and rates of cardiovascular events or mortality. However, in
90% of the 10 patients (7.1%) having a postoperative cardio-
vascular event and in 80% of the 5 patients who died (3.6%),
ASA was not being taken. Surgical morbidity was not signifi-
cantly influenced by resumption of ASA treatment. Of 20
patients (14.3%) who developed a surgical complication, only 1
patient (5%) was taking ASA treatment.
ASA Therapy and Intracranial Surgery
Studies investigating the effect of ASA in cranial neurosurgery
are sparse and mostly based on case reports.14 In 1979, Merriman
et al17 first reported on 2 neurosurgical patients who developed
postoperative hematomas allegedly secondary to ASA-induced
platelet defect. Stroobandt et al18 identified ASA as a possible
predisposing factor for cSDH in 16% of 132 patients with
subdural hematoma. The question of whether preoperative low-
dose ASA should be discontinued before elective intracranial
surgery has never been satisfactorily answered.14 In a mail survey
of neurosurgeons’ opinions on perioperative use of antiplatelet
agents, Korinth14 reported that 19.6% of the respondents had no
policy or guidelines concerning this issue at their clinic.
Furthermore, 77.5% of the neurosurgeons felt that patients
undergoing ASA therapy were at a higher bleeding risk
perioperatively, and 12.9% noted a personal experience with
bleeding complications in patients taking low-dose ASA. To the
TABLE 6. Cardiovascular Events and Mortalitya
Total (n = 140)
ASATherapy
P ValueDiscontinuedb (n = 131) Resumedc (n = 9)
Myocardial infarction 4 3 1 .24
ST-segment–elevation myocardial infarction 1 1 . . .
Non–ST-segment–elevation myocardial infarction 3 2 1
Other cardiovascular events 6 6 0 ..99
Occlusion of femoral artery 1 1 . . .
Pulmonary embolism 3 3 . . .
Cardiac arrhythmia/decompensation 2 2 . . .
All cardiovascular events 10 9 1 .5
Mortality 5 4 1 .21
aASA, acetylsalicylic acid.
bASA resumed .5 days postoperatively.
cASA resumed ,5 days postoperatively.
TABLE 7. Implication of Our Results for Daily Practicea
Patient Type Recommendation Rationale
No indication for primary or
secondary CAD prevention
ASA treatment should not be resumed
postoperatively.
Our results show a trend toward lower recurrence rates in
patients who never resumed ASA treatment postoperatively.
Primary CAD prevention Discontinuation of ASA treatment
during the perioperative period of
cSDH (eg 4-6 wk) might be justified.
ASA does not seem to affect cardiovascular mortality.7,20
Therefore the risk for cardiovascular events does not exceed
the risk of having a recurrent cSDH.
Secondary CAD prevention Discontinuation of ASA treatment for 7-
10 d, thereafter resumption of ASA
treatment.
The benefit of ASA treatment for secondary CAD prevention is
well known.7,19
These decisions should be individualized, taking into account
the specific cardiovascular risk profile of each patient.
The estimated OR and RD for a recurrent event, depending on
the timing of resuming ASA treatment provided in Table 4, can
become essential aids in this decision making.
Caution should be taken in patients
with low postoperative GCS score or
high postoperative mRS score.
In our study, low postoperative GCS score and worse
postoperative mRS score were found to be independent risk
factors for the recurrence of cSDH.
aASA, acetylsalicylic acid; CAD, coronary artery disease; cSDH, chronic subdural hematoma; GCS, Glasgow Coma scale; mRS, modified Rankin Scale.
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best of our knowledge, no previous studies have evaluated cSDH
recurrence rates in patients taking antiplatelet therapy and related
to timing of resuming ASA postoperatively.
The Implication of Our Results for Daily Practice
Our results showed a trend toward lower cSDHrecurrence rates in
patients who never resumed low-doseASApostoperatively (P = .07).
Given this trend and other published findings, we recommend that,
before ASA treatment is resumed after surgical evacuation of cSDH,
its indication should be evaluated. If no definitive, guideline-based
primary or secondary prevention indication exists, ASA should not
be resumed (Table 7).
In the setting of primaryCADprophylaxis, ASAdoes not seem to
affect perioperative cardiovascular mortality.7,19 Our data show
a trend toward higher recurrence rates of cSDH in patients in
whom ASA therapy was resumed at any time. Therefore, in
patients taking low-dose ASA for primary CAD, its discontinu-
ation for 4 to 6 weeks postoperatively might be justified (Table 7).
The benefits of ASA treatment for secondary CAD prevention are
wellknown.7,19 Our results show no significant increase in recurrence
rates with earlier resumption of ASA. Considering our results and
other published data, in patients under ASA treatment for secondary
CAD prophylaxis, withdrawal of ASA treatment for 7 to 10 days
might be justified. However, these decisions should be individualized,
taking into account the specific cardiovascular risk profile of each
patient. We believe that the estimated OR and RD for a recurrent
event, depending on the timing of resuming ASA treatment (Table
4), can become essential aids in this decision making.
In our cohort, 84.2% of the recurrences (n = 16) occurred
before postoperative day 42. Up to this time point, we estimated
a continuous increase (1%/wk) when resuming ASA therapy
earlier. However, after day 42, the risk of recurrence, even if ASA
therapy is resumed, does not continue to increase in a linear
fashion. Rather, the risk for recurrence after day 42 seems low;
therefore, ASA treatment should be reinstated, at the latest, by 6
weeks postoperatively.
The overall rate of major postoperative thrombotic events in our
cohort was lower than expected. A possible explanationmight be that
in patients with a strong indication for ASA use (eg, history of
myocardial infarction), treatment was resumed earlier or, alterna-
tively, not discontinued at all, and thus our patients received adequate
preventive treatment during the perioperative period.Of note, in 108
patients (77%), the fact that ASA was not discontinued until the day
of the operation might also explain the low percentage of cardiovas-
cular events. Interestingly, no association with lower recurrence rates
in patients in whomASAwas discontinued 5 days preoperatively was
seen. These results are slightly surprising because after ASA therapy is
discontinued, a period of 5 to 6 days is required to replace
approximately 50% of the circulating platelets (10%/24 h).20,21
Therefore, these patients may have still been under partial
antithrombotic effect during the operation and in the early
perioperative period. Moreover, if postoperative ASA therapy were
continued early (eg, within 5 days), the patient might have even
been under continuous ASA treatment effect. In contrast, studies
have also shown that in line with the ASA withdrawal syndrome, half
of the patients demonstrate normal platelet function at 72 hours,
and 80% normalized at 96 hours from the last aspirin dose.7,22
Study Limitations
This retrospective study is subject to all the limitations of data
collection inherent in such works. ASA resumption was based on
surgeons’ decision making, which obviously causes a selection
bias. However, this bias is almost unavoidable because the
indication for ASA and the patient’s condition will always play
a role in the decision making for when to restart ASA treatment
postoperatively. The incidence of thrombotic events under
discontinued ASA medication in our cohort was slightly lower
than reported in the literature (6.9% vs 10.1%). This might be
due to the fact that patients were not screened for thrombotic
events. Therefore, some cardiovascular events such as an
asymptomatic myocardial infarction/ischemia or myocardial
injury after noncardiac surgery might have been missed.
CONCLUSION
In patients undergoing burr-hole drainage for cSDH, early and
late resumption of low-dose ASA therapy showed comparable
recurrence rates. In face of the risk of cardiovascular events, in
patients treated for secondary CAD, resumption of ASA treatment
after 7 to 10 days may be warranted. Further prospective studies
with a larger cohort are needed to confirm our results.
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COMMENTS
T he authors present a retrospective analysis of their experience withresumption of low-dose aspirin in a population of patients who
underwent burr-hole drainage of chronic subdural hematoma. They
are to be commended for attempting to answer a question that so
commonly comes up on rounds in the hospital. Their cohort of pa-
tients is fairly sizeable, given the specifics: only patients on low-dose
aspirin undergoing surgery for chronic subdural hematoma. Unfor-
tunately, the results really show no statistically significant differences
in timing of resumption and recurrence of hematoma or even in
thrombotic complications. This may actually be a desired result in that
individual practitioners may feel comfortable with either holding the
aspirin for a specified time for worry of recurrence or in resuming it
early with the knowledge that there does not seem to be increased risk.
Some important “trends” may help to guide management, specifically
that early resumption (after 7 days) for patients deemed high risk for
a thrombotic event was safe and that never resuming aspirin for
patients having no good indication for it may decrease the risk for
recurrence long term. The authors acknowledge the limitations and
bias in this retrospective analysis.
Despite the lack of statistical significance, this article adds to our
knowledge base and can help practitioners to develop their own
protocol for resumption of aspirin. However, caution is advised in
attempts to extrapolate the data in that all of these patients were
on low-dose (100 mg once daily) aspirin. Conclusions cannot be




T his is a retrospective analysis with data that will add to our under-standing and assist in guiding clinical decisions regarding this nuanced
management issue.
In reviewing the recommendations, however, the strength of the article
holds in focusing on stated results rather than on information that is based
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